EU nod for Vertex CF therapy Kaftrio
Clearance was based on two global Phase III studies showing statistically significant improvements in lung function
Read More
Tag: F508del mutation
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
